The metabolic syndrome as a concept of adipose tissue disease

Hypertension Research

Volumn 31, Issue 7, 2008, Pages 1283-1291

  Oda, Eiji ^a  

^a Tachikawa Medical Center   (Japan)

Author keywords

Cardiovascular disease; Diabetes; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; C-REACTIVE PROTEIN; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; WAIST-HIP RATIO;

EID: 50449083989     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1283     Document Type: Review

References (103)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
3. Kaplan NM: The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
4. Lemieux I, Pascot A, Couillard C, et al: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-184.
5. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
6. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
7. Iso H, Kobayashi M, Ishihara J, et al: Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) Study Cohort 1. Circulation 2006; 113: 195-202.
8. Ouellet V, Marois J, Weisnagel SJ, Jacques H: Dietary cod protein improves insulin sensitivity in insulin-resistant men and women. Diabetes Care 2007; 30: 2816-2821.
9. Riserus U, Arnlov J, Berglund L: Long-term predictors of insuli resistance. Role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 2928-2933.
10. Oh SW, Yoon YS, Lee ES, et al: Association between cigarette smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey. Diabetes Care 2005; 28: 2064-2066.
11. Gustat J, Srinivasan SR, Elkasabany A, Berenson GS: Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. J Clin Epidemiol 2002; 55: 997-1006.
12. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
13. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 90: 1929-1935.
14. Lee D, Lee I, Jin S, Steffes M, Jacobs DR Jr: Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2007; 30: 622-628.
15. Ruderman NB, Schneider SH, Berchtold P: The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981; 34: 1617-1621.
16. Nakamura T, Tokunaga K, Shimomura I, et al: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239-246.
17. Lamarche B, Tchernof A, Mauriege P, et al: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-1961.
18. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva, World Health Organization, 1999.
19. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetes Med 1999; 16: 442-443.
20. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. Einhorn D, Reaven GM, Cobin RH, et al: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252.
22. Alverti KGMM, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
23. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
24. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
25. Grundy SM: Does the metabolic syndrome exist? Diabetes Care 2006; 29: 1689-1692.
26. Kahn R: The metabolic syndrome (emperor) wears no clothes. Diabetes Care 2006; 29: 1693-1696.
27. Reaven GM: The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237-1247.
28. Grundy SM: Does a diagnosis of metabolic syndrome have value in clinical practice. Am J Clin Nutr 2006; 83: 1248-1251.
29. Ferrannini E: Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007; 92: 396-398.
30. Grundy SM: Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
31. Kahn R: Metabolic syndrome. Is it a syndrome? Does it matter. Circulation 2007; 115: 1806-1811.
32. Beaser RS, Levy P: Metabolic syndrome. A work in progress, but a useful construct. Circulation 2007; 115: 1812-1818.
33. Sundstrom J, Vallhagen E, Riserus U, et al: Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006; 29: 1673-1674.
34. Eckel RH, Kahn R, Robertson RM, Rizza RA: Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113: 2943-2946.
35. Malik S, Wong ND, Franklin SS, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
36. McNeil AM, Rosamond WD, Girman CJ, et al: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385-390.
37. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005; 28: 1769-1778.
38. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
39. The DECODE Study Group, Qiao Q: Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837-2846.
40. Gami AS, Witt BJ, Howard DE, et al: Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007; 49: 403-414.
41. Ninomiya T, Kubo M, Doi Y, et al: Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 2007; 38: 2063-2069.
42. Sone H, Tanaka S, Ishibashi S, et al: The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions. Diabetes Care 2006; 29:145-147.
43. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN: The importance of waist circumference in the definition of metabolic syndrome. Prospective analyses of mortality in men. Diabetes Care 2006; 29: 404-409.
44. Chen H, Pan W: Probable blind spot in the International Diabetes Federation definition of metabolic syndrome. Obesity 2007; 15: 1096-1100.
45. Yoon YS, Lee ES, Park C, Lee S, Oh SW: The new definition of metabolic syndrome by the International Diabetes Federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised National Cholesterol Education Program: the Korea NHANES Study. IntJ Obes 2007; 31: 528-534.
46. Tong PC, Kong AP, So W, et al: The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1206-1211.
47. Tanomsup S, Aekplakorn W, Sritara P, et al: A comparison of components of two definitions of the metabolic syndrome related to cardiovascular disease and all-cause mortality in a cohort study in Thailand. Diabetes Care 2007; 30: 2138-2140.
48. Lorenzo C, Serrano-Rios M, Maritinez-Larrad MT, et al: Is waist circumference an essential component of the metabolic syndrome? Diabetes Care 2007; 30: 2141-2142.
49. Klein S, Allison DB, Heymsfield SB, et al: Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 2007; 30: 1647-1652.
50. Oda E: Criteria for diagnosing the metabolic syndrome. Am J Clin Nutr 2006; 84: 1251-1252.
51. Ogden CI, Carroll MD, Cutin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
52. Ministry of Health, Labour and Welfere, Japan: The National Health and Nutrition Survey in Japan, 2004. Tokyo, Daiichi Shuppan, 2004 (in Japanese).
53. Adabs KF, Schatzkin A, Harris TB, et al: Overweight, obesity, and mortality in a large prospective cohort of 50 to 71 years old. N Engl J Med 2006; 355: 763-778.
54. Chei CL, Iso H, Yamagishi K, Inoue M, Tsugane S, JPHC Study Group: Body mass index and weight change since 20 years of age and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based Study. Int J Obes (Lond) 2008; 32: 144-151.
55. Kissebah AH, Vydelingum N, Murray R, et al: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254-260.
56. Despres J, Nadeau A, Tremblay A, et al: Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38: 304-309.
57. Pouliot MC, Despres J, Lemieux S, et al: Waist circumference and abdominal saggital diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-468.
58. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB: Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555-563.
59. Matsuzawa YM: Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997; 13: 3-13.
60. Fox CS, Massaro JM, Hoffmann U, et al: Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
61. Pou KM, Massaro JM, Hoffmann U, et al: Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 2007; 116: 1234-1241.
62. Kelley DE, Goodpaster BH: Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 2001; 24: 933-941.
63. Montani UP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG: Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular disease. Int J Obes Relat Metab Disord 2004; 28: 558-565.
64. Rasouli N, Molavi B, Elbein SC, Kern PA: Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 2007; 9 (1): 1-10.
65. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
66. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
67. Zhang Y, Proenca I, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
68. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophy Res Commun 1996; 221: 286-298.
69. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
70. Fukuhara A, Matsuda M, Nishizawa M, et al: Visfatin: a protein secreted by visceral fat that mimicks the effects of insulin. Science 2005; 307: 426-430.
71. Takahashi K, Mizuarai S, Araki H, et al: Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003; 278: 46654-46660.
72. Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
73. Xu A, Wang Y, Xu JY, et al: Adipocyte fatty acid binding protein a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
74. Dandona P, Aljada A, Mohanty P, et al: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-3265.
75. 2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2006; 54: S73-S78.
76. Semenkovich CF: Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-1822.
77. Kim JY, Wall E, Laplante M, et al: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-2637.
78. Bains RK, Wells SE, Flavell DM, et al: Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology 2004; 145: 2666-2679.
79. Cinti S, Mitchell G, Barbatelli G, et al: Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347-2355.
80. Kanda H, Tateya S, Tamori Y, et al: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
81. Kamei N, Tobe K, Suzuki R, et al: Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-26614.
82. Wellen KE, Fucho R, Gregor MF, et al: Coordinated regulation of nutrient and inflammatory response by STAMP2 is essential for metabolic homeostasis. Cell 2007; 129: 537-548.
83. Strissel KJ, Stancheva Z, Miyoshi H, et al: Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007; 56: 2910-2918.
84. Kolak M, Westerbacka J, Velagapudi VR, et al: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960-1968.
85. Han TS, Satter N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-2021.
86. Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
87. Nakanishi S, Yamane K, Kamei N, et al: Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003; 26: 2754-2757.
88. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PWF: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.
89. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-1959.
90. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R: Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693.
91. Doi Y, Kiyohara Y, Kubo M, et al: Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population. Diabetes Care 2005; 28: 2497-2500.
92. Dehghan A, van Hoek M, Sijbrand EJG, Stijnen T, Hofman A, Witteman JCM: Risk of type 2 diabetes attributable to Creactive protein and other risk factors. Diabetes Care 2007; 30: 2695-2699.
93. Sabatine MS, Morrow DA, Jablonski KA, et al: Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528-1536.
94. Shamsuzzaman ASM, Winnicki M, Wolk R, et al: Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-2185.
95. Matsushita K, Yatsuya H, Tamakoshi K, et al: Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men. Atherosclerosis 2006; 188: 184-189.
96. Nakamura H, Ito H, Egami Y, et al: Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008; 79: 330-336.
97. Komatsu M, Ohfusa H, Aizawa T, Hashizume K: Adiponectin inversely correlates with high-sensitivity C-reactive protein and triglycerides, but not with insulin sensitivity in apparently healthy Japanese men. Endocrine J 2007; 54: 553-558.
98. Yoneda M, Mawatari H, Fujita K, et al: High-sensitivity Creactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-582.
99. Oda E, Oohara K, Abe A, et al: The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan. Circ J 2006; 70: 384-388.
100. Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Kishii R: Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. Hypertens Res 2006; 29: 589-596.
101. Matsushita K, Yatsuya H, Tamakoshi K, et al: High-sensitivity C-reactive protein is quite low in Japanese men at high coronary risk. Circ J 2007; 71: 820-825.
102. Itoh T, Mizuno Y, Harada E, Yoshimura M, Ogawa H, Yasue H: Coronary spasm is associated with chronic lowgrade inflammation. Circ J 2007; 71: 1074-1078.
103. Christakis NA, Fowler JH: The spread of obesity in a large social network over 32 years. N Engl J Med 2007; 357: 370-379.